# REGENERON PHARMACEUTICALS, INC. (REGN) · Edgar & Edgarette company card

> Regeneron Pharmaceuticals (REGN) grew revenue 1.0% in FY2025 to $14.3 billion, operating margin 24.9% against a -3.8% median for pharmaceutical preparations, equity 77.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 872589 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/REGN) · [JSON](https://www.pops4.com/boards/company/REGN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $14.3B |
| Revenue growth, 1 year | 1.0% |
| Revenue growth per year | -2.8% |
| Operating margin | 24.9% (prior year 28.1%) |
| Net margin | 31.4% |
| Operating cash flow | $5.0B |
| Capital spending | $898M |
| Free cash flow | $4.1B |
| Cash | $3.1B |
| Long-term debt | $2.0B |
| Total assets | $40.6B |
| Total equity | $31.3B |
| Equity ÷ assets | 77.1% |
| Return on equity | 14.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 9.21 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $14.3B (FY2025), total debt $2.0B. Experience: revenue up 1.0% on the year, down 2.8% a year over 4 years; operating margin 24.9%, down from 28.1%. Soundness: equity 77.1% of assets, return on equity 14.4%, payout 8.2% of profit. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $12.0B and $17.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $10.3B to $19.6B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 24.9% against a -3.8% median; growth 1.0% against 13.7%.

Range logged 2026-09-26, receipt 98172bd39eb3b358, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-30 ([filing](https://www.sec.gov/Archives/edgar/data/872589/000110465926112340/0001104659-26-112340-index.htm))

## Recent filings

- 10-Q · filed 2026-10-30 · [filing](https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm)
- 8-K · filed 2026-10-30 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/0000872589-26-000032-index.htm)
- 8-K · filed 2026-10-06 · 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm)
- 8-K · filed 2026-09-30 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/872589/000110465926112340/0001104659-26-112340-index.htm)
- 10-Q · filed 2026-07-30 · [filing](https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/0000872589-26-000023-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000872589.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=872589

## Cite

POPS4, Edgar & Edgarette: REGENERON PHARMACEUTICALS, INC. (REGN) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/REGN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.